Adial Pharmaceuticals Completes Private Placement of Common Stock at $4.00 Per Share

Rhea-AI Summary

Adial Pharmaceuticals (NASDAQ: ADIL; ADILW) announced it received $720,000 from an $800,000 private placement, originally disclosed on November 10, 2021. The shares, priced at $4.00 each, were fully subscribed with 200,000 shares purchased. This funding was confirmed following the SEC's Notice of Effectiveness for the Form S-3 Registration Statement. Adial is focused on addiction therapies, particularly its lead investigational drug, AD04, which is under evaluation in the ONWARD™ Phase 3 trial aimed at treating Alcohol Use Disorder.

Positive

• Successfully secured $720,000 from a fully subscribed private placement.
• No additional warrants or broker fees incurred during the Offering.

Negative

• None.

CHARLOTTESVILLE, Va., Dec. 22, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that it has received the balance of $720,000 due from the $800,000 private placement previously disclosed by the Company on November 10, 2021 (the “Offering”). The shares of common stock sold in the Offering were priced at $4.00 per share and a total of 200,000 shares (the “Shares”) were purchased in the Offering. The Offering was fully subscribed.

The Shares were purchased pursuant to a Securities Purchase Agreement (“SPA”) by Bespoke Growth Partners, Inc. (“Bespoke”), a long-time strategic investor in Adial. Bespoke is controlled by Adial’s Chief Strategy Officer, Mark Peikin. The payment of the balance of funds due was triggered by Securities and Exchange Commission’s December 16, 2021, Notice of Effectiveness of the Form S-3 Registration Statement registering the Shares.

No warrants, options, rights or other securities were issued or granted and no broker fees were incurred by Adial in connection with the Offering.

About Adial Pharmaceuticals, Inc.

Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of treatments for addictions. The Company’s lead investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) and is currently being investigated in the Company’s landmark ONWARD™ pivotal Phase 3 clinical trial for the potential treatment of AUD in subjects with certain target genotypes, which are to be identified using the Company’s proprietary companion diagnostic genetic test. A Phase 2b clinical trial of AD04 for the treatment of AUD showed promising results in reducing frequency of drinking, quantity of drinking and heavy drinking (all with statistical significance), and no overt safety concerns (there were no statistically significant serious adverse events reported). AD04 is also believed to have the potential to treat other addictive disorders such as Opioid Use Disorder, gambling, and obesity. The Company is also developing adenosine analogs for the treatment of pain and other disorders. Additional information is available at www.adialpharma.com.

About Purnovate, Inc.

Purnovate, Inc., a wholly owned subsidiary of Adial Pharmaceuticals, is a pharmaceutical development and chemistry company focused on inventing and developing selective, potent, stable, and soluble adenosine analogs to treat diseases and disorders such as pain, cocaine addiction, inflammation, infectious disease, cancer, asthma, and diabetes. Additional information is available at www.purnovate.com.

Forward Looking Statements

This communication contains certain "forward-looking statements" within the meaning of the U.S. federal securities laws. Such statements are based upon various facts and derived utilizing numerous important assumptions and are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Statements preceded by, followed by or that otherwise include the words "believes," "expects," "anticipates," "intends," "projects," "estimates," "plans" and similar expressions or future or conditional verbs such as "will," "should," "would," "may" and "could" are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing. The forward-looking statements include statements regarding the potential of AD04 to treat other addictive disorders such as opioid use disorder, gambling, and obesity, and the invention and development of selective, potent, stable, and soluble adenosine analogs to treat diseases and disorders such as pain, cocaine addiction, inflammation, infectious disease, cancer, asthma, and diabetes. Any forward-looking statements included herein reflect our current views, and they involve certain risks and uncertainties, including, among others, our ability to enroll patients within the timelines anticipated and complete clinical trials on time and achieve desired results and benefits as expected, our ability to obtain regulatory approvals for commercialization of product candidates or to comply with ongoing regulatory requirements, regulatory limitations relating to our ability to promote or commercialize our product candidates for specific indications, acceptance of our product candidates in the marketplace and the successful development, marketing or sale of our products, our ability to maintain our license agreements, the continued maintenance and growth of our patent estate, our ability to establish and maintain collaborations, our ability to obtain or maintain the capital or grants necessary to fund its research and development activities, and our ability to retain our key employees or maintain our Nasdaq listing. These risks should not be construed as exhaustive and should be read together with the other cautionary statement included in our Annual Report on Form 10-K for the year ended December 31, 2020, subsequent Quarterly Reports on Form 10-Q and current reports on Form 8-K filed with the Securities and Exchange Commission. Any forward-looking statement speaks only as of the date on which it was initially made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances or otherwise, unless required by law.

Contact:
Crescendo Communications, LLC
David Waldman / Natalya Rudman
Tel: 212-671-1021
Email: adil@crescendo-ir.com

FAQ

What was the amount raised by Adial Pharmaceuticals in its private placement?

Adial Pharmaceuticals raised $720,000 from its private placement.

What is the price per share from Adial's recent stock offering?

The shares in Adial's recent offering were priced at $4.00 each.

How many shares were purchased in Adial's private placement?

A total of 200,000 shares were purchased in Adial's private placement.

Who is the strategic investor in Adial Pharmaceuticals' private placement?

Bespoke Growth Partners, Inc. was the strategic investor in Adial's private placement.

What is the focus of Adial Pharmaceuticals?

Adial Pharmaceuticals focuses on developing therapies for addiction and related disorders.